Niels Svenstrup
Corporate Officer/Principal chez PEPGEN INC.
Fortune : 147 000 $ au 31/03/2024
Profil
Niels Svenstrup is currently the SVP-Chemistry, Manufacturing & Control at PepGen Inc. Prior to this, he was the Senior Vice President-Development at Cydan II, Inc. from 2017 to 2021.
He was also the Director-CMC at Ascendis Pharma A from 2015 to 2017 and the Head-Medicinal Chemistry Department at H.
Lundbeck A from 2008 to 2015.
Dr. Svenstrup holds a graduate and doctorate degree from the University of Southern Denmark.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PEPGEN INC.
0,03% | 01/03/2024 | 10 000 ( 0,03% ) | 147 000 $ | 31/03/2024 |
Postes actifs de Niels Svenstrup
| Sociétés | Poste | Début |
|---|---|---|
| PEPGEN INC. | Corporate Officer/Principal | 01/04/2021 |
Anciens postes connus de Niels Svenstrup
| Sociétés | Poste | Fin |
|---|---|---|
Cydan II, Inc.
 Cydan II, Inc. Pharmaceuticals: GenericHealth Technology Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/04/2021 |
| ASCENDIS PHARMA A/S | Corporate Officer/Principal | 01/07/2017 |
| H. LUNDBECK A/S | Corporate Officer/Principal | 01/11/2015 |
Formation de Niels Svenstrup
| University of Southern Denmark | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| H. LUNDBECK A/S | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| PEPGEN INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Cydan II, Inc.
Cydan II, Inc. Pharmaceuticals: GenericHealth Technology Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA. | Health Technology |
